Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Phathom Pharmaceuticals Inc (NQ: PHAT )

10.34 +0.30 (+2.99%)
Streaming Delayed Price Updated: 10:56 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Phathom Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Recap: Phathom Pharmaceuticals Q3 Earnings
Via Benzinga
Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity
  
Via Benzinga
Analyst Expectations for Phathom Pharmaceuticals's Future
Via Benzinga
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Preview: Phathom Pharmaceuticals's Earnings
Via Benzinga
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's Going On With Phathom Pharmaceuticals Stock?
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo 
Via Benzinga
Exposures Product Safety
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
Via Benzinga
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 469 companies hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
$14M Bet On This Technology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
One Analyst Is Bullish While Another Sees Overhang On Phathom Pharma Stock After Two Rejection Letters
FDA issued two Complete Response Letters to Phathom Pharmaceuticals Inc's (NASDAQ: PHAT) vonoprazan marketing application for the erosive esophagitis (EE) indication and H. pylori (HP) indication... 
Via Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.